Targeted radiation zaps Hard-to-Treat prostate cancer in early trial
NCT ID NCT07363486
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new radioactive drug called 225Ac-LNC1011 in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein (PSMA) on cancer cells to deliver radiation directly. Nine participants will receive up to 4 doses to find the safest and most effective amount.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
225Ac-LNC1011 (a radioactive drug that targets prostate cancer cells)
What this could lead to
If it works, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a very early, small trial with only 9 participants, so results may not apply to everyone. The radioactive drug can cause side effects like fatigue, low blood counts, or damage to healthy organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••